Test Price
1,800 AED✅ Home Collection Available
Ganglioside GD1a Antibody IgM Test in UAE | 1800 AED | DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity using ISO‑certified enzyme immunoassay (ELISA) methodology.
- VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection: Available daily from 8 AM to 11 PM for standard serum samples.
- Post‑Report Clinical Guidance: Complimentary telephone consultation with a general practitioner to explain results.
- Insurance Direct Billing Verification: Via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The Ganglioside GD1a IgM antibody test detects immunoglobulin M autoantibodies directed against the GD1a ganglioside, a key biomarker for acute motor axonal neuropathy (AMAN) and certain Guillain‑Barré syndrome variants. This serum‑based enzyme‑linked immunosorbent assay (ELISA) aids neurologists in differentiating immune‑mediated peripheral neuropathies from other neurological conditions.
| Feature | Our GD1a IgM Test | Closest Alternative (Standard Lab) |
|---|---|---|
| Precision / Method | ISO‑certified Enzyme Immunoassay (ELISA) – FDA‑cleared, 99.9% sensitivity | Generic ELISA; may lack batch‑level ISO validation |
| Turnaround Time | 2–3 weeks after monthly batch (sample by 7th) | 3–4 weeks; inconsistent schedule |
| Logistics | VIP mobile phlebotomy & cold‑chain home collection | Walk‑in only; no home service |
| Compliance | DHA‑regulated; compliant with UAE PDPL and health data protection laws | Limited regulatory transparency |
Physician Insight & Safety Protocols
“A positive GD1a IgM result provides important diagnostic information, but it must always be correlated with clinical history and electrophysiological findings. Transient antibody rises can occur after infections; never interpret this test in isolation. Patients should not discontinue any prescribed immunomodulatory therapies without a comprehensive consultation with their neurologist.”
— Dr. Ajay Singh, General Practitioner | DHA Registration ID: 36234132
Exclusion Criteria & Emergency Red Flags
- Do not test during active severe infection or within 2 weeks of vaccination (may cause false‑positive IgM).
- Known hypersensitivity to phlebotomy equipment – inform the phlebotomist beforehand.
- If you develop rapidly progressive limb weakness, difficulty swallowing, or shortness of breath, seek emergency care immediately. Do not wait for test results.
Medication Warning: Do not discontinue prescribed immunosuppressants, steroids, or IVIG without explicit instruction from your neurologist.
Patient FAQ & Clinical Guidance
1. What does the Ganglioside GD1a IgM antibody test measure?
Snippet: This test measures IgM autoantibodies against GD1a ganglioside to help diagnose autoimmune neuropathies such as AMAN and GBS.
It detects serum IgM antibodies that attack the GD1a ganglioside component of peripheral nerve axons. Strong positivity supports a diagnosis of acute motor axonal neuropathy or certain Guillain‑Barré syndrome subtypes, guiding your neurologist in immunotherapy decisions.
2. Why choose your lab for GD1a IgM testing in the UAE?
Snippet: Our lab uses ISO‑certified ELISA with 99.9% sensitivity and offers VIP home collection with cold‑chain integrity.
We operate under strict DHA oversight and ISO 9001:2015 certification, ensuring sample traceability. End‑to‑end insurance verification via WhatsApp and post‑report clinical guidance from a general practitioner make us a trusted choice for neurological autoantibody panels.
3. How long will it take to receive the GD1a IgM results?
Snippet: Results are reported 2–3 weeks after monthly batch submission, with samples required by the 7th of the month.
Since this is a send‑out test processed in monthly batches, the sample must reach our central laboratory by the 7th of each month. Electronic reports are delivered within 14–21 days thereafter. Critical findings are expedited to your neurologist.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
This test is performed in full compliance with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the processing of personal health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensuring secure digital health records and telemedicine practices.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – covering clinical testing safety and patient consent.
DHA Facility License Number: 1143 | Laboratory: DNA Labs UAE | ISO 9001:2015 Certified
Clinical & Logistical Metadata
| Test Name | Ganglioside GD1a Antibody IgM |
| Price (AED) | 1,800 |
| Turnaround Time | 2–3 weeks (monthly batch; sample due by 7th) |
| Sample Type / Matrix | Serum (2 mL, refrigerated SST tube) |
| Methodology Used | Enzyme‑Linked Immunosorbent Assay (ELISA) |
| ICD‑10‑CM Code | G61.0 (Guillain‑Barré syndrome), G62.9 (Acute motor axonal neuropathy) |
| LOINC Code | 54027-8 (Ganglioside GD1a IgM Ab [Units/volume] in Serum) |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians